Connect with us


CytoDyn Inc (OTCMKTS: CYDY) Announces Appointments of New Chief Operating Officer and Senior Executive Vice President



CytoDyn Inc (OTCMKTS: CYDY) has announced that it has appointed Nitya Ray, Ph.D., to act as its Chief Operating Officer and Christopher Recknor as its Senior Executive Vice President of Clinical Operations. Dr. Ray, who has worked more than thirty years in the biotech industry, was one of the first members to work on product development for Leronlimab (PRO 140).

CytoDyn will remain focused on BLA resubmission

The new appointments align with CytoDyn’s goals to change its management structure to advance clinical development and improve the BLA resubmission process.

The appointees’ teams will hire more personnel to complement another hire, Dr. Srinivasan, the CMC Regulatory affairs executive director.

CytoDyn’s main objective remains the BLA submission. Dr. Ray will be in charge of CMC activities and regulatory submissions. Dr. Recknor, on the other hand, will focus on none clinical and clinical activities.

According to Nader Pourhassan, Ph.D., the CEO of CytoDyn, the CMC package for BLA indicates the expertise provided by Dr. Ray and his team. His past performance has enabled the company to have 1.2 million vials of leronlimab ready to be delivered.

The company was able to get a Fast Track Designation from the U.S Food and Drug Administration(FDA) for leronlimab to treat metastatic cancer and Human Immunodeficiency Virus (HIV) in combination with HAART therapy.

How leronlimab works

Leronlimab works by binding to CCR5, which is a crucial cellular receptor in tumour metastasis and HIV. By binding to CCR5 in HIV patients, it prevents the R5 strain of the virus from entering T-cells, thus protecting them from infection. The drug does not work on other HIV strains. It only works on R5, which is the most dominant.

There have been clinical trials, 5 of which show that the drug significantly controls or lowers HIV viral load in patients. Compared to other HIV drugs, it is administered less frequently and has more minor side effects.

Scientists are also testing leronlimab’s efficacy in the treatment of metastatic cancer. It might block CCR5 which plays a role in angiogenesis, tumour metastases, and invasion. The drug lowers breast cancer metastasis in humans using a murine xenograft model by approximately 97%.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.


Business4 hours ago

CV Sciences Inc. (OTCMKTS: CVSI) Reports 8% Drop In Sales In Q3 2021 Attributable To Regulatory Uncertainty in CBD

Post Views: 7 CV Sciences Inc. (OTCMKTS: CVSI) has announced its third-quarter 2021 financial results for the period ending September...


AuxlyCannabis Group Inc. (OTCMKTS: CBWTF) Reports Net Revenue Growth 95% In Q3 2021

Post Views: 44 Auxly Cannabis Group Inc. (OTCMKTS: CBWTF) has announced its financial results for the third quarter and nine...


Vivo Cannabis Inc. (OTCMKTS: VVCIF) Releases Q3 2021 Net Revenue of $6.2 Million as It Expands Internationally

Post Views: 31 Vivo Cannabis Inc. (OTCMKTS: VVCIF) has released its Q3 2021 operating and financial results for the quarter...

Business6 hours ago

Rubicon Organics Inc. (OTCMKTS: ROMJF) Announces 124% YoY Growth In Revenue in Q3 2021 After Launching New Brands

Post Views: 11 Rubicon Organics Inc. (OTCMKTS: ROMJF) has released its Q3 2021 results ending September 30, 2021, in which...

Business1 day ago

Sugarbud Craft Growers Corp (OTCMKTS: SBUDF) Reports 120% Sequential Revenue Growth in Q3 2021

Post Views: 14 Sugarbud Craft Growers Corp (OTCMKTS: SBUDF) has filed its unaudited consolidated preliminary financial statements for the quarter...

Business1 day ago

Indiva Limited (OTCMKTS: NDAF) Reports 143% YoY increase in Revenue In Q3 2021

Post Views: 46 Indiva Limited (OTCMKTS: NDAF) has announced its operating and financial results for the third quarter ending September...